Diagnostic accuracy by ROC and univariate, unadjusted survival analysis by Cox proportional regression
Parameters | AUC by ROC (95% CI) | Optimal cut-off | HR | 95% CI | χ2 |
Age, years | 0.51† (0.35 to 0.67) | >72 | 1.3† | 0.79 to 2.1 | – |
Sex | 0.65† (0.49 to 0.81) | Male | 2.7†(0.05) | 1.0 to 7.2 | 4.2†(0.054) |
Heart rate, /min | 0.70* (0.56 to 0.84) | >80 | 1.8* | 1.0 to 7.2 | 5.7* |
Haemoglobin, g/dL | 0.56† (0.39 to 0.74) | ≥14.4 | 1.4† | 0.9 to 2.3 | – |
WHO FC | 0.60† (0.46 to 0.75) | >II | 1.7†(0.086) | 0.9 to 3.3 | 3.6†(0.071) |
6MWT, m | 0.66† (0.51 to 0.80) | <330 | 1.8†(0.081) | 0.9 to 3.6 | 3.4†(0.064) |
NTproBNP, pg/mL | 0.67* (0.59 to 0.91) | ≥4140 | 2.8*** | 1.6 to 4.8 | 18.2*** |
cTnT, ng/L | 0.63† (0.51 to 0.87) | ≥28 | 2.1** | 1.2 to 3.7 | 8.6** |
LV-EF, % | 0.70* (0.54 to 0.86) | >75 | 2.1** | 1.2 to 3.5 | 9.2** |
RA-ESABSA, cm2/m2 | 0.68* (0.50 to 0.85) | ≥15 | 1.7* | 1.0 to 2.9 | 4.7* |
RV-EDD, mm | 0.68* (0.51 to 0.85) | >48 | 2.1** | 1.3 to 3.4 | 7.8** |
TAPSE, mm | 0.71* (0.55 to 0.88) | <16 | 2.3** | 1.3 to 3.9 | 10.2** |
RV-FAC, % | 0.61† (0.43 to 0.78) | <22 | 1.7† | 0.8 to 11.4 | – |
RV-ASI, % | 0.69* (0.52 to 0.87) | <37 | 1.7* | 1.5 to 2.8 | 4.4* |
LV-EI | 0.68** (0.51 to 0.86) | ≥1.7 | 2.5** | 1.5 to 4.2 | 11.9*** |
TASV, cm/s | 0.51† (0.33 to 0.68) | <10 | 1.2† | 0.7 to 2.0 | – |
Tei-Index | 0.56† (0.39 to 0.73) | ≥0.72 | 1.1† | 0.6 to 1.7 | – |
RV-2Dstrain, −% | 0.78** (0.62 to 0.90) | ≤│12│ | 2.3** | 1.4 to 3.9 | 10.5*** |
RV-MMI, mm Hg*% | 0.85*** (0.76 to 0.95) | ≤0.31 | 3.3** | 1.6 to 7.0 | 16.0*** |
ESC/ERS PAH risk score | 0.64† (0.49 to 0.79) | >10% | 1.9* | 1.0 to 3.5 | 4.4* |
*P<0.05, **P<0.01, ***P<0.001.
†Not significant.
6MWT, 6 min walk test; ASI, automated systolic index; AUC, area under the curve; BSA, body surface area; cTnT cardiac troponin T; EDD, end-diastolic diameter; ERS, European Respiratory Society; ESC, European Society of Cardiology; FAC, fractional area change; FC, functional class; LV-EF, left ventricular ejection fraction; LV-EI, left ventricular eccentricity index; NTproBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; RA-ESA, right atrial end-systolic area; ROC, receiver operating characteristics; RV, right ventricular; RV-2Dstrain, two-dimensional strain; RV-MMI, right ventricular myo-mechanical index; TAPSE, tricuspid annular plane systolic excursion; TASV, tricuspid annular systolic velocity.